Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

FDA approves use of enzalutamide in chemotherapy-naive mCRPC

This afternoon the U.S. Food & Drug Administration approved enzalutamide (Xtandi) as a treatment for patients with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) based on the results of the PREVAIL trial. … READ MORE …

DCVAC/PCa and the VIABLE trial in men with mCRPC

It has been brought to our attention that a Czech company called Sotio, based in Prague, has recently initiated a randomized, multi-center, Phase III clinical trial (known as the VIABLE trial) of what appears to be a “second-generation” form of activated dendritic cell-based immunotherapy for the treatment of advanced prostate cancer. … READ MORE …

Cabozantinib shows no survival benefit in COMET-1 trial

Exelixis has announced that the COMET-1 trial of cabozantinib in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) has failed to show a statistically significant survival benefit. The company has also stopped enrollment into the COMET-2 trial. … READ MORE …

New form of experimental immunotherapy for men with progressive mCRPC

A company called Advaxis is planning to test a new form of prostate cancer immunotherapy (ADXS-PSA) in combination  with an investigational drug called pembrolizumab (an anti-PD-1 immune checkpoint inhibitor) in men with previously treated, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Enzalutamide and quality of life in post-chemotherapy mCRPC patients

A newly published paper in The Lancet Oncology has provided data on several of the prospectively defined secondary endpoints from the AFFIRM trial of enzalutamide vs. a placebo in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC) after progression on treatment with docetaxel + prednisone. … READ MORE …

Phase I/II data on ODM-201 in mCRPC; and a Phase III trial in nmCRPC

ODM-201 is a new androgen receptor  inhibitor, initially developed by a Finnish company called Orion and now being developed by Orion in partnership with the German pharmaceutical company, Bayer. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers